The new leukemia drug Xospata is aiming to expand insurance benefit standards again. According to related industries, Astellas Pharmaceutical Korea submitted an application to expand the salary of Acute Myeloid Leukemia treatment Xospata at the end of last year and is currently discussing the schedule for the cancer disease review committee with the HIRA. Looking at the current benefit criteria, two-cycle benefits are recognized as induction therapy for patients who are non-responsive to existing treatments or can perform homogeneous hematopoietic stem cell transplantation among FLT3 mutation-positive AML patients. However, considering the preparation period for allogeneic hematopoietic stem cell transplantation, add